Filing Details

Accession Number:
0000899243-20-026348
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-25 19:00:55
Reporting Period:
2020-09-23
Accepted Time:
2020-09-25 19:00:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367644 Emergent Biosolutions Inc. EBS Pharmaceutical Preparations (2834) 141902018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380185 Fuad El-Hibri 400 Professional Drive, Suite 400
Gaithersburg MD 20879
Chairman Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-23 13,000 $100.58 1,136,523 No 4 S Direct
Common Stock Disposition 2020-09-24 12,535 $98.85 1,123,988 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,140,463 Indirect By Intervac L.L.C
Common Stock 1,524,155 Indirect By Biovac L.L.C.
Footnotes
  1. The transaction was made by the Reporting Person pursuant to a trading plan adopted by Fuad El-Hibri Nancy El-Hibri JTWROS on February 25, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").
  2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.86 to $102.63. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.84 to $100.44. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. Intervac is the direct owner of 2,140,463 shares of the Issuer's common stock. The Reporting Person serves as the managing member of Intervac and the Reporting Person or his wife serve as the trustee of each of the members of Intervac. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
  5. The Reporting Person, individually, and the Reporting Person and his wife, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C., which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. The Reporting Person disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.